EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial

Yi-Lu Zhang, Li-Jing Jiao, Ya-Bin Gong, Jian-Fang Xu, Jian Ni, Xiao-Yong Shen, Jie Zhang, Di Zhou, Cheng-Xin Qian, Qin Wang, Jia-Lin Yao, Wen-Xiao Yang und 8 weitere

Chinese Journal of Integrative Medicine · 2024

DOI: 10.1007/s11655-024-4114-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Chinese Journal of Integrative Medicine, 2024. Verfasst von Yi-Lu Zhang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Sh…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drugs, Chinese Herbal, Patient Reported Outcome Measures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate whether the combination of chemotherapy with staged Chinese herbal medicine (CHM) therapy could enhance health-related quality of life (QoL) in non-small-cell lung cancer (NSCLC) patients and prolong the time before deterioration of lung cancer symptoms, in comparison to chemotherapy alone. METHODS: A prospective, double-blind, randomized, controlled trial was conducted from December 14, 2017 to August 28, 2020. A total of 180 patients with stage I B-IIIA NSCLC from 5 hospitals in Shanghai were randomly divided into chemotherapy combined with CHM (chemo+CHM) group (120 cases) or chemotherapy combined with placebo (chemo+placebo) group (60 cases) using stratified blocking randomization. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life-Core 30 Scale (QLQ-C30) was used to evaluate the patient-reported outcomes (PROs) during postoperative adjuvant chemotherapy in patients with early-stage NSCLC. Adverse events (AEs) were assessed in the safety analysis. RESULTS: Out of the total 180 patients, 173 patients (116 in the chemo+CHM group and 57 in the chemo+placebo group) were included in the PRO analyses. The initial mean QLQ-C30 Global Health Status (GHS)/QoL scores at baseline were 57.16 ± 1.64 and 57.67 ± 2.25 for the two respective groups (P>0.05). Compared with baseline, the chemo+CHM group had an improvement in EORTC QLQ-C30 GHS/QoL score at week 18 [least squares mean (LSM) change 17.83, 95% confidence interval (CI) 14.29 to 21.38]. Conversely, the chemo+placebo group had a decrease in the score (LSM change -13.67, 95% CI -22.70 to -4.63). A significant between-group difference in the LSM GHS/QoL score was observed, amounting to 31.63 points (95% CI 25.61 to 37.64, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrugs, Chinese HerbalPatient Reported Outcome MeasuresQuality of LifeHumansMaleMiddle AgedFemaleDouble-Blind MethodChemotherapy, AdjuvantAgedPostoperative PeriodProspective Studies

Stichwörter der Autor:innen

Chinese herbal medicineadjuvant chemotherapyhealth-related quality of lifenon-small-cell lung cancerpatient-reported outcome

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • Oncology Department, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
  • Institute of Traditional Chinese Medicine Oncology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
  • Oncology Department, Shanghai Pulmonary Hospital, Shanghai Tongji University, Shanghai, 200433, China.
  • Thoracic Surgery Department, Huadong Hospital, Shanghai Fudan University, Shanghai, 200040, China.
  • Thoracic Surgery Department, Shanghai Cancer Hospital, Shanghai Fudan University, Shanghai, 200032, China.
  • Oncology Department, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China. drchenzhiwei@163.com.

Zitieren

APA

Zhang, Y. L., Jiao, L. J., Gong, Y. B., Xu, J. F., Ni, J., Shen, X. Y., Zhang, J., Zhou, D., Qian, C. X., Wang, Q., Yao, J. L., Yang, W. X., Su, L. Z., Wang, L. Y., Li, J. Q., Yao, Y. Q., Zhang, Y. H., Wang, Y. C., Chen, Z. W., & Xu, L. (2024). Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial. Chinese Journal of Integrative Medicine. https://doi.org/10.1007/s11655-024-4114-9

Vancouver

Zhang YL, Jiao LJ, Gong YB, Xu JF, Ni J, Shen XY, et al. Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial. Chinese Journal of Integrative Medicine. 2024. doi:10.1007/s11655-024-4114-9

BibTeX
@article{Zhang2024,
  author = {Zhang, Yi-Lu and Jiao, Li-Jing and Gong, Ya-Bin and Xu, Jian-Fang and Ni, Jian and Shen, Xiao-Yong and Zhang, Jie and Zhou, Di and Qian, Cheng-Xin and Wang, Qin and Yao, Jia-Lin and Yang, Wen-Xiao and Su, Ling-Zi and Wang, Li-Yu and Li, Jia-Qi and Yao, Yi-Qin and Zhang, Yuan-Hui and Wang, Yi-Chao and Chen, Zhi-Wei and Xu, Ling},
  title = {Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {Chinese Journal of Integrative Medicine},
  year = {2024},
  doi = {10.1007/s11655-024-4114-9}
}
Kostenlos starten →